



Enzymotec Ltd.
Investor Relations Department
Sagi 2000 Industrial Park P.O. Box6
Migdal HaEmeq 23106
Israel

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: ENZY ¹

Last Trade:	8.15
Trade Time:	4:00 PM ET Jun 27, 2017
Change:	0.15 (1.875%)
Day Range	8.00 - 8.15
52-Week Range	5.20 - 9.32
Volume	4,836
Market Cap. (\$M)	187.043
Shares Out (M)	22.950


¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

We are a leading global supplier of specialty lipid-based products and solutions. We develop, manufacture and market innovative bio-functional lipid ingredients, as well as final products, based on sophisticated proprietary processes and technologies. We deliver our products and solutions through the following two reportable segments:

1. Nutrition segment: This segment develops and manufactures nutritional ingredients for infant formulas and dietary supplements. These ingredients include InFat - which is sold and marketed by Advanced Lipids, our joint venture with AAK, InFat is a proprietary, clinically-proven infant formula fat ingredient that more closely resembles human breast milk fat to facilitate healthy infant development. Other ingredients are premium phospholipid-based bioactive ingredients for nutritional supplements. Our best-selling nutritional ingredient for dietary supplements is krill oil, which provides the benefits of omega-3 fatty acids. Our other nutritional ingredients for dietary supplements are targeted at improving brain health and providing benefits in memory, learning abilities and

Stock Performance



Press Releases [\[View all \]](#)

Jun 6, 2017

[Enzymotec Launches Next Generation Krill Oil Product - K•REAL® Gold](#)

May 25, 2017

[Enzymotec Ltd. to Present at the Jefferies 2017 Global Healthcare Conference](#)

May 17, 2017

[Enzymotec Ltd. Reports First Quarter 2017 Unaudited Financial Results](#)

May 3, 2017

[Enzymotec to Report First Quarter 2017 Financial Results](#)

Apr 3, 2017

[Neptune and Enzymotec Reach Patent Agreement Ending All Litigation](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

Mar 16, 2017

[Annual Report for Foreign Private Issuers \(20-F\)](#)

- concentration.
2. VAYA Pharma segment:
This segment develops, manufactures and sells branded lipid-based medical foods for the dietary management of medical disorders and common diseases. This is a research-based, specialty pharmaceutical segment, which currently offers medical foods products for the cardiovascular and neurological markets. Our VAYA Pharma products are currently the only products sold by us for use by end users.

... [\(more\)](#)